BLACK FRIDAY SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim→
logo
Market statusData NSENot investment advice
NATH BIO-GENES (I)

NATH BIO-GENES (I) Latest Share Price (NATHBIOGEN)

₹132.73
0.61−0.46%
Overall Score63/100
Day range132
₹132.73
134
52-week126
₹132.73
204
Above low+5.2%
Below high34.9%
Range position8%
Open133.95
Prev Close133.34
Bid132.70100
Ask132.76100

TODAY IN ONE LINE

NATHBIOGEN slipped 0.5% on light volume, lagging Nifty's 1.1% move.

With a market cap of ₹252.75 Cr., it trades at a P/E of 8.00. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume2.2K−62%vs 20D avg
Price Band20
Lower Band104.3
Upper Band156.44
Tick Size0.01
Daily Volatility2.26%
Annualised Vol43.18%
Market Cap₹252.75 Cr.
Promoter45.6%
Face Value₹10
Fwd P/E—
PEG1.78
EV/EBITDA11.21
P/S0.7
ROA2.85%
Beta1.07
Div Payout9.54%
THE STOCK SCORE
Overall Score63/100
Updated 07 Sept

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

NATH BIO-GENES (I) flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 2 red flags

Green Flags

  • ●Reasonable ValuationTrading at a moderate P/E of 7.6x
  • ●Steady Dividend YieldReliable 1.50% dividend yield
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.20x
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • ●Sales ContractionQuarterly sales dropped 87.6% YoY
  • ●Poor Capital ReturnsLow ROE of 6.1%

Latest NATH BIO-GENES (I) News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

NATH BIO-GENES (I) valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for NATH BIO-GENES (I), framed against the sector median so the premium or discount is obvious at a glance.

NATH BIO-GENES (I) trades at a P/E of 8.00× and P/B of 0.43×.

Key MetricsMarket + reported · 20 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹252.75 Cr.
P/E Ratio
8
P/B Ratio
0.43
EPS
₹0.22
Profitability

Profitability

ROE
6.12%
ROCE
-0.03%
Net Margin
9.35%
Op Margin
14.46%
Growth

Growth

EPS YoY
—
Revenue YoY
-1%
Qtr Sales
-87.59%
Qtr Profit
-98.7%
Financial Health

Financial Health

Debt / Equity
0.2
Book Value
₹358.06
Div Yield
1.5%
Promoter Holding
45.6%
Technicals

NATH BIO-GENES (I) technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NATH BIO-GENES (I) — derived from the latest tape, not yesterday's close.

NATH BIO-GENES (I) last traded at ₹132.73 with an intraday range of ₹132.01–₹134 — latest indicator, pivot and CPR signals below.

Last updated: 22 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹132.73
LevelPrice (₹)Distance% Δ
R4137.80+5.07+3.82%
R3135.81+3.08+2.32%
R2134.90+2.17+1.64%
R1133.82+1.09+0.82%
PIVOT132.910.180.14%
CURRENT132.73——
S1131.83-0.90-0.68%
S2130.92-1.81-1.36%
S3129.84-2.89-2.18%
S4127.85-4.88-3.68%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 132.82P: 132.91TC: 133.00
R1
R2
R3
R4
indicator
LTP: 132.73
PDH: 137.80
PDL: 133.00
● Market Sentiment

NATHBIOGEN is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Narrower, suggesting likely for trending moves

● Opening Range

Day's range: ₹133.1–₹133.95

● Price Position

Trading Below opening range, showing Bearishness

Financials

NATH BIO-GENES (I) financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for NATH BIO-GENES (I) — consolidated or standalone — with margins, YoY growth and key ratios inline.

NATH BIO-GENES (I) reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹252.75 Cr. and reported EPS of ₹0.22.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026May 2026
Revenue from Operations445
445
▲ 0.0%
Sales Growth YoY %Derived21.98%
—
Other Income8
8
▲ 0.0%
Total Income453
453
▲ 0.0%
202
202
▲ 0.0%
Gross ProfitDerived244
244
▲ 0.0%
Gross Margin %Derived54.73%
54.73%
191
191
▲ 0.0%
EBITDA (Operating Profit)Derived52
52
▲ 0.0%
OPM %Derived11.78%
11.78%
26
26
▲ 0.0%
Profit Before Tax (PBT)46
46
▲ 0.0%
5
5
▲ 0.0%
Effective Tax %Derived10.09%
10.09%
Total Profit for Period42
42
▲ 0.0%
Net Profit (Owner's PAT)Derived42
42
▲ 0.0%
Net Profit Margin %Derived9.35%
9.35%
PAT Growth YoY %Derived7.85%
—
Earnings Per Share (EPS ₹)21.91
21.91
▲ 0.0%
Diluted Shares Outstanding (Cr)2
2
▲ 0.0%
Share of Profit from Associates/JVs—
—
Other Comprehensive Income (Net of Tax)-2
-2
▲ 0.0%
Total Expenses (incl. D&A & Interest)407
407
▲ 0.0%
Material Cost % of RevenueDerived68.79%
68.79%
Employee Cost % of RevenueDerived8.04%
8.04%
Other Cost % of RevenueDerived34.91%
34.91%
Interest Coverage (x)Derived3.03x
3.03x
Sales CAGR · 3Y
+6.8%
Sales CAGR · 5Y
+6.0%
PAT CAGR · 3Y
+2.6%
PAT CAGR · 5Y
+1.0%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

NATH BIO-GENES (I) segment analysis : revenue and profit mix.

Disclosed business segments at NATH BIO-GENES (I) with their share of revenue and profit, switchable between consolidated and standalone reporting.

NATH BIO-GENES (I) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for NATH BIO-GENES (I).

Our AI distills the core fundamental drivers supporting NATH BIO-GENES (I), the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 10 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

Shareholding

NATH BIO-GENES (I) shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in NATH BIO-GENES (I) — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Public54.21%↑0.08%
DII0.01%
FII0.19%↓0.08%
Promoters45.60%

Ownership Distribution

Retail & Public
54.21%
Foreign Institutions
0.19%
Promoters
45.60%

Category Trends

Foreign Institutions Breakdown
Total Holding: 0.19%
Net Change: -0.08%
Detailed Institutions1 institutions
Total Holding0.00%
Net Change+0.00%
Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
KAVI GLOBAL OPPORTUNITY MASTER FUND LP
0.00%
0.00%
0.00%
Sep 2026
Peers

NATH BIO-GENES (I) peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NATH BIO-GENES (I) is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
LT FOODS
₹15,105.5 Cr
Best Profit Growth
CHAMAN LAL SETIA EXP
75.97 %
Highest Dividend Yield
NATH BIO-GENES (I)
1.50 %
09 · Chart Patterns

NATH BIO-GENES (I) chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for NATH BIO-GENES (I) — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

NATH BIO-GENES (I) delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for NATH BIO-GENES (I) over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in NATH BIO-GENES (I) stood at 72.7% of traded volume, against a 20-day average of 75.6%.

Avg Delivery (20D)75.6%-2.9 ppt latest vs avg
Highest Delivery89%on 17 Nov
Avg Volume (20D)5.8 K20-day run-rate
Conviction Trend↓ Weakening-2.9 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

NATH BIO-GENES (I) announcements: results, concalls, ratings, M&A.

Filings NATH BIO-GENES (I) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

NATH BIO-GENES (I) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 43 documents below.

  1. 14 Nov 2026General UpdatesView PDF

    General Updates

    Nath Bio-Genes (India) Limited has informed the Exchange about General Updates

  2. 14 Nov 2026Outcome of Board MeetingView PDF

    Outcome of Board Meeting

    Nath Bio-Genes (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

  3. 12 Nov 2026General UpdatesView PDF

    General Updates

    Nath Bio-Genes (India) Limited has informed the Exchange about General Updates

  4. 21 Oct 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018View PDF

    Certificate under SEBI (Depositories and Participants) Regulations, 2018

    Nath Bio-Genes (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  5. 28 Sept 2026Trading WindowView PDF

    Trading Window

    Nath Bio-Genes (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…

Corporate Actions

NATH BIO-GENES (I) dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue NATH BIO-GENES (I) has declared, sequenced by announce and record date.

NATH BIO-GENES (I) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About NATH BIO-GENES (I): business, sector, key facts.

What NATH BIO-GENES (I) does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

NATH BIO-GENES (I) operates in the Other Agricultural Products industry under the Fast Moving Consumer Goods sector, listed as NSE: NATHBIOGEN, BSE: 537291.

NATHBIOGEN
Fast Moving Consumer Goods

NATH BIO-GENES (I)

NSE · NATHBIOGEN·BSE · 537291·nathbiogenes.com

Nath Bio-Genes (India) Limited is a prominent player in the Indian agricultural sector, specializing in the production, processing, and marketing of hybrid and genetically modified (GM) seeds. Their business model encompasses both domestic and international markets, contributing to a diverse and expansive reach within the industry. The company's activities are primarily focused on providing a comprehensive range of seeds tailored to various agricultural needs.

The company's operations are structured around two core segments: Agricultural Activities and Trading Activities. The Agricultural Activities segment focuses on the cultivation and processing of a wide spectrum of seeds. This includes fiber and oil seeds such as cotton and mustard, which are crucial components of the textile and edible oil industries, respectively. In addition, they offer seeds for various field crops, encompassing cereals like bajra, corn, paddy, wheat, and jowar, contributing to food security and agricultural output. Their portfolio extends to fruit seeds and a comprehensive selection of vegetable seeds, covering a wide variety of popular crops.

Beyond seeds, Nath Bio-Genes also offers a line of crop protection supplements under the brand names WINPro GOLii, WINall, and Win Chi Win. These supplements are designed to enhance crop health, yield, and resilience, addressing critical aspects of modern agriculture. Furthermore, the company supplies forage seeds under the NUTRIMAX GOLD and NUTRIMAX brands, catering to livestock farming and related industries. This diversification into related agricultural products enhances their market positioning and strengthens their customer relationships.

The Trading Activities segment complements their agricultural production, encompassing the buying and selling of agricultural commodities and related products. This vertical integrates with their seed production and crop protection supplement businesses, facilitating efficient market access and supply chain management. The integration between the agricultural and trading activities allows for a more holistic approach to serving the agricultural market, from seed production to post-harvest management and distribution.

Established in 1979 and headquartered in Mumbai, India, Nath Bio-Genes (India) Limited has cultivated a significant presence in the agricultural landscape. Their extensive product portfolio, coupled with their focus on both domestic and international markets, positions them as a key contributor to India's agricultural sector and a significant player in the global seed market.

company facts
Employees—
SectorFast Moving Consumer Goods
HeadquartersMumbai, India
Market Cap₹252.75 Cr.
Listed OnNSE
leadership20 on record
Abhinay Jadhav
Chief People Officer
Anil Khed
Vice President
Dr. Devinder Gurusharan Khurana
Executive Vice President
Mr. Amol Arunrao Gupta
Chief Financial Officer
Mr. Amol Gupta
Chief Financial Officer
Mr. Dhiraj Rajesh Rathi
Company Secretary & Compliance Officer
Mr. Dhiraj Rathi
Compliance Officer, Company Secretary
Mr. Harish B. Pandey
Vice President of Marketing
Mr. Hitesh Purohit
Additional Independent Director
Mr. Madhukar Deshpande
Additional Independent Director
Mr. Ravinder K. Reddy
Vice President
Mr. Satish Kagliwal
Managing Director, Director
§ ∞ · Plainly Answered

Questions investors ask about NATH BIO-GENES (I) (NATHBIOGEN).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of NATH BIO-GENES (I) (NATHBIOGEN)?

The current share price of NATH BIO-GENES (I) (NATHBIOGEN) is ₹132.73. Today, the stock has declined by ₹0.61 (0.46%), trading in a range of ₹132.01 to ₹134.00. The stock opened at ₹133.95 with a trading volume of 2,217 shares.

02Is NATH BIO-GENES (I) stock a good investment for long-term?

NATH BIO-GENES (I) can be considered for long-term investment based on several factors. The company has a market capitalization of ₹252.75 Cr., P/E ratio of 8, ROE of 6.12%, and ROCE of -0.03%. The dividend yield stands at 1.5%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of NATH BIO-GENES (I) stock?

The 52-week high price of NATH BIO-GENES (I) (NATHBIOGEN) is ₹204.00, while the 52-week low is ₹126.15. Currently trading at ₹132.73, the stock is 5.22% above its 52-week low and 34.94% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy NATH BIO-GENES (I) stock at the current price?

Whether to buy NATH BIO-GENES (I) stock at ₹132.73 depends on multiple factors. The stock is currently trading with a P/E ratio of 8 and P/B ratio of 0.43. Today's performance shows a loss of 0.46%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of NATH BIO-GENES (I) and when is the next dividend?

NATH BIO-GENES (I) offers a dividend yield of 1.5%, which means for every ₹100 invested at the current price of ₹132.73, you can expect to receive approximately ₹1.50 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of NATH BIO-GENES (I)?

NATH BIO-GENES (I)'s key financial metrics include: P/E Ratio: 8, P/B Ratio: 0.43, ROE: 6.12%, ROCE: -0.03%, Dividend Yield: 1.5%, EPS: ₹0.22, Book Value: ₹358.06, and Debt-to-Equity: 0.2. The company's market cap stands at ₹252.75 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is NATH BIO-GENES (I) stock performing today in the market?

NATH BIO-GENES (I) stock opened at ₹133.95 and is currently trading at ₹132.73, showing a decline of ₹0.61 (0.46%). The intraday high is ₹134.00 and low is ₹132.01. The trading volume stands at 2,217 shares, indicating moderate market participation today.

08What is the P/E ratio of NATH BIO-GENES (I) and what does it indicate?

NATH BIO-GENES (I) has a Price-to-Earnings (P/E) ratio of 8, which means investors are willing to pay 8.00 for every ₹1 of earnings. With an EPS of ₹0.22, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about NATH BIO-GENES (I) (NATHBIOGEN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.